Interferon Treatment Improves Survival among Liver Transplant Recipients with Recurrent Hepatitis C
Journal Title: Journal of Surgery - Year 2013, Vol 1, Issue 1
Abstract
Hepatitis C in the liver allograft recipient has an aggressive course. A significant proportion of such recipients develop graft fibrosis and cirrhosis within five years of transplantation. Treatment efficacy with standard or pegylated interferon and ribavirin is suboptimal compared to the immunocompetent individuals. However, the effect of such therapy on graft and patient survival remains unknown. Objectives: To determine the efficacy of interferon based therapies in liver transplantation recipients with recurrent hepatitis C, and to determine the effect of interferon treatment on graft and patient survival. Methods: We retrospectively analyzed 823 hepatitis C patients, who underwent liver transplantation at Thomas E Starzl Transplantation Institute, University of Pittsburgh between January 1992 and April 2006. Two hundred and sixty four patients received either interferon (all kinds) monotherapy, or combination therapy. The primary end point was graft failure and death. Results: Both treated and untreated groups were similar in clinical characteristics at the time of transplantation. In treatment group, 77% received prednisone based immunosuppression as compared to 75% in no treatment group. 57% of patients in treatment group had HCV RNA >1 million units/ml after transplantation. Patients were categorized into four groups; no treatment (n=440), ≤ 24 weeks of treatment (n=38), 25-48 weeks of treatment (n=64) and >48 weeks of treatment (162). Total bilirubin > 2 at 6 and 12 months and an AST/ALT ratio of >1 at 6 month of transplantation are independently associated with poor patient survival. Patients who received treatment for >48 weeks have significantly improved survival independent of sustained viral response (HR 0.33, p=< 0.001). Conclusion: Among liver transplant recipients with recurrent hepatitis C, treatment with any interferon with or without ribavirin for >48 weeks is significantly associated with improved patient survival regardless of viral response. Prospective trials are indicated to confirm these findings.
Authors and Affiliations
Shahid Habib
Keywords
Related Articles
- EP ID EP203756
- DOI 10.13188/2332-4139.1000007
- Views 122
- Downloads 0
Trans Oral-Substernum Incision Thoracic Endoscopic Surgery: A Minimally Invasive Endoscopic Approach in Thoracic Surgery
Flexible endoscope is used in Natural Orifice Trans-luminal Endoscopic Surgery. Cervical incision thoracic surgery has recently been described. The use of a flexible endoscope through a natural orifice into the thoracic...
Comparison of J-Shaped Incision and Mercedes Incision for Liver Transplantation
Wound-related and incision-related complications such as wound infections and incisional hernias are common after liver transplantation. Advances in surgical, anesthesiological, critical care, and immunological innovatio...
A Case-Series of Solitary Skull Neoplastic Lesions Treated with En-Block Resection and Complex Cranioplasty
Background and aims: Tumors involving the calvarium but extending into the adjacent scalp layers and/or the underlying dura and brain are technically challenging to treat. Patients often present late in the course of dis...
Invasive Procedures withQuestionable Indications used in Russia: Recent History
This review summarizes a series of reports on invasive procedures applied with questionable clinical indications. The following topics are discussed: the overuse of the Halsted and Patey mastectomy, relatively high negat...
Clinical Outcome of Supracricoid Partial Laryngectomy: Experience on 31 Patients
Objective: Supracricoidpartial laryngectomy with Cricohyoidoepiglottopexyor Cricohyoïdopexieis an organ preservation surgery indicated for selected T1 to T3 laryngeal cancers. To evaluate functional and oncological outco...